KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2023)

Historic Restructuring Costs for Nektar Therapeutics (NKTR) over the last 2 years, with Q4 2023 value amounting to $1.9 million.

  • Nektar Therapeutics' Restructuring Costs fell 3154.26% to $1.9 million in Q4 2023 from the same period last year, while for Sep 2024 it was $1.9 million, marking a year-over-year decrease of 7035.06%. This contributed to the annual value of $5.5 million for FY2023, which is 8267.13% down from last year.
  • According to the latest figures from Q4 2023, Nektar Therapeutics' Restructuring Costs is $1.9 million, which was down 3154.26% from $652000.0 recorded in Q3 2023.
  • In the past 5 years, Nektar Therapeutics' Restructuring Costs registered a high of $106.0 million during Q2 2022, and its lowest value of $652000.0 during Q3 2023.